Table 3.
The association between pulmonary function tests, laboratory parameters, PET/CT findings and progression at the end of a 1-year follow-up
| Progression present (n=10) | Progression absent (n=30) | P | |
| Laboratory Findings | |||
| NLR | 6.1 (±5.0) | 2.7 (±1.0) | =0.001 |
| RDW (fl) | 14.9 (±2.2) | 15.2 (±2.1) | >0.05 |
| MPV (fl) | 8.3 (±0.9) | 8.3 (±0.9) | >0.05 |
| Hemoglobin (gr/dL) | 13.3 (±1.9) | 13.0 (±1.4) | >0.05 |
| ESR (mm/H) | 28.7 (±15.5) | 30.3 (±22.8) | >0.05 |
| ACE (U/L) | 55.9 (±36.7) | 59.4 (±48.7) | >0.05 |
| Calcium (mEq/L) | 9.6 (±0.4) | 9.4 (±0.6) | >0.05 |
| Pulmonary Function Test, | |||
| FEV1 (lt) | 2.25 (±0.33) | 2.19 (±0.39) | >0.05 |
| FEV1% | 81.7 (±7.1) | 80.8 (±6.1) | >0.05 |
| FVC (lt) | 2.84 (±0.45) | 2.67 (±0.63) | >0.05 |
| FVC% | 84.2 (±10.3) | 87.5 (±16.5) | >0.05 |
| FEV1/FVC | 76.6 (±6.0) | 80.2 (±8.2) | >0.05 |
| DLCO ml/mmHg/min | 14.5 (±6.4) | 17.6 (±3.8) | >0.05 |
| DLCO% | 59.8 (±21.5) | 73.3 (±13.9) | =0.02 |
| DLCO/VA | 4.02 (±0.99) | 4.13 (±0.93) | >0.05 |
| DLCO/VA% | 85.0 (±18.8) | 85.2 (±18.1) | >0.05 |
| PET/CT SUV, mean (SD) | |||
| Lymph node PET/CT SUVmax | 13.4 (±8.4) | 7.5 (±3.4) | =0.04 |
| Lung parenchyma PET/CT SUVmax | 3.0 (±0.6) | 3.2 (±1.7) | >0.05 |
NLR, neutrophil-to-lymphocyte ratio. MPV, mean platelet volume (fl)=[platelet crit(%)/platelet count (×109/l)] × 105. ACE, angiotensin converting enzyme. FEV1, forced expiratory volume in 1 s. FVC, forced vital capacity. DLCO, diffusing capacity of lung. DLCO/VA, diffusing capacity divided by the alveolar volume. PET/CT SUVmax, Positron Emission Tomography - Computed Tomography Maximum Standardized Uptake Value.
Data are expressed as mean±standard deviation.